The study is designed to determine the safety and tolerability of RN316 when administered intravenously to healthy adult subjects. This is the first time RN316 has been given to humans.

Inclusion Criteria:

• Healthy, ambulatory men and women (of non-childbearing potential) ages 18 -70 inclusive.
• Baseline total cholesterol ≥ 200 mg/dl, baseline LDL ≥ 130 mg/dl.
• BMI 18.5 to 35, and body weight ≤150 kg, inclusive.

Exclusion Criteria:

• Evidence of clinically significant disease that may increase the risk to the subject of study participation or interfere with interpretation of results.
• Secondary hyperlipidemia.
• Subjects who have taken lipid lowering compounds within the past 12 months prior to dosing.